• Bernhardt R (2006). Cytochromes P450 as versatile biocatalysts. J Biotechnol 124: 128145.
  • Davydov DR (2011). Microsomal monooxygenase as a multienzyme system: the role of P450-P450 interactions. Expert Opin Drug Metab Toxicol 7: 543558.
  • Dutton GJ (1980). Acceptor substrates of UDP glucuronosyltransferase and their assay. Pp. 6978in G. J. Dutton, ed. Glucuronidation of drugs and other compounds. CRC Press, Boca Raton, FL.
  • Fremont JJ, Wang RW, King CD (2005). Coimmunoprecipitation of UDP-glucuronosyltransferase isoforms and cytochrome P450 3A4. Mol Pharmacol 67: 260262.
  • Fujiwara R, Itoh T (2014). Extensive protein-protein interactions involving UDP-glucuronosyltransferase (UGT) 2B7 in human liver microsomes. Drug Metab Pharmacokinet 29: 259265.
  • Ishii Y, Iwanaga M, Nishimura Y, Takeda S, Ikushiro S, Nagata K, et al. (2007). Protein-protein interactions between rat hepatic cytochromes P450 (P450s) and UDP-glucuronosyltransferases (UGTs): evidence for the functionally active UGT in P450-UGT complex. Drug Metab Pharmacokinet 22: 367376.
  • Ishii Y, Koba H, Kinoshita K, Oizaki T, Iwamoto Y, Takeda S, et al. (2014). Alteration of the function of the UDP-glucuronosyltransferase 1A subfamily by cytochrome P450 3A4: different susceptibility for UGT isoforms and UGT1A1/7 variants. Drug Metab Dispos 42: 229238.
  • Lang S, Erdmann F, Jung M, Wagner R, Cavalie A, Zimmermann R (2011). Sec61 complexes form ubiquitous ER Ca2+ leak channels. Channels (Austin) 5: 228235.
  • Lewis DF (2004). 57 varieties: the human cytochromes P450. Pharmacogenomics 5: 305318.
  • Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, et al. (2005). Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15: 677685.
  • Mori Y, Kiyonaka S, Kanai Y (2011). Transportsomes and channelsomes: are they functional units for physiological responses? Channels (Austin) 5: 387390.
  • Nakajima M, Yokoi T (2005). Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation. Drug Metab Pharmacokinet 20: 227235.
  • Reed JR, Backes WL (2012). Formation of P450 · P450 complexes and their effect on P450 function. Pharmacol Ther 133: 299310.
  • Shepherd SR, Baird SJ, Hallinan T, Burchell B (1989). An investigation of the transverse topology of bilirubin UDP-glucuronosyltransferase in rat hepatic endoplasmic reticulum. Biochem J 259: 617620.
  • Subramanian M, Low M, Locuson CW, Tracy TS (2009). CYP2D6-CYP2C9 protein-protein interactions and isoform-selective effects on substrate binding and catalysis. Drug Metab Dispos 37: 16821689.
  • Subramanian M, Tam H, Zheng H, Tracy TS (2010). CYP2C9-CYP3A4 protein-protein interactions: role of the hydrophobic N terminus. Drug Metab Dispos 38: 10031009.
  • Takeda S, Ishii Y, Iwanaga M, Nurrochmad A, Ito Y, Mackenzie PI, et al. (2009). Interaction of cytochrome P450 3A4 and UDP-glucuronosyltransferase 2B7: evidence for protein-protein association and possible involvement of CYP3A4 J-helix in the interaction. Mol Pharmacol 75: 956964.
  • Taura KI, Yamada H, Hagino Y, Ishii Y, Mori MA, Oguri K (2000). Interaction between cytochrome P450 and other drug-metabolizing enzymes: evidence for an association of CYP1A1 with microsomal epoxide hydrolase and UDP-glucuronosyltransferase. Biochem Biophys Res Commun 273: 10481052.
  • Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, et al. (2004). Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32: 12011208.
  • Zheng Y, Sun D, Sharma AK, Chen G, Amin S, Lazarus P (2007). Elimination of antiestrogenic effects of active tamoxifen metabolites by glucuronidation. Drug Metab Dispos 35: 19421948.